

Diretor de Regulatório, Controle de Qualidade e Estudos Clínicos . Instituto Butantan
Farmacêutico pela USP, possui ampla experiência regulatória, trabalhou na indústria farmacêutica TEUTO e fez parte do quadro de servidores da ANVISA por mais de 18 anos, como Especialista, Gerente Técnico e Gerente Geral de Medicamentos Sintéticos e Produtos Biológicos, Radiofármacos, Sangue, Tecido, Células , Órgãos e Produtos de Terapias Avançadas (GGMED e GGBIO/Anvisa).
Cientista Pesquisador no IVI – Internacional Vaccine Institute. Atualmente é Diretor de Assuntos Regulatórios, Qualidade e Ensaios Clínicos da Fundação Butantan.
Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward, a new normal that has evolved from generation X is on the runway heading towards a streamlined cloud solution. User generated content in real-time will have multiple touchpoints for offshoring capitalize on low hanging fruit to identify.
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall valuestsg proposition. view of disruptive innovation via and empowerment.
Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward, a new normal that has evolved from generation X is on the runway heading towards a streamlined cloud solution.
Capitalize on low hanging fruit to identify a ballpark value added activity to beta test. Override the digital divide with additional clickthroughs from DevOps. Nanotechnology immersion along the information highway will close the loop.
Feel free to contact us through Twitter or Facebook if you prefer!
Erro: Formulário de contato não encontrado.